We believe that the challenges of future medicine can only be solved by an interdisciplinary approach. On the one hand, biomarker-driven drug development follows common strategies, on the other hand, only joint efforts will transform the health care system. Therefore, the 6th Munich Biomarker Conference is open to various indications, including, but not limited to, oncology, respiratory diseases, immunology and infection, neurological disorders and orphan diseases.